NeoGenomics Inc. (NEO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

NeoGenomics Inc. (NEO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.87

1.24 (9.82%)

At close: Jan 14, 2025, 3:59 PM

13.78

-0.61%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	13.65
Market Cap	1.78B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.61
PE Ratio (ttm)	-22.73
Forward PE	n/a
Analyst	Buy

Ask	13.95
Volume	2,355,067
Avg. Volume (20D)	782,360
Open	12.72
Previous Close	12.63
Day's Range	12.26 - 13.88
52-Week Range	12.13 - 19.11
Beta	undefined

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fl...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Mar 16, 2004

Employees 2,100

Stock Exchange NASDAQ

Ticker Symbol NEO

Website https://www.neogenomics.com

Analyst Forecast

According to 10 analyst ratings, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 40.64% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

NeoGenomics Inc. is scheduled to release its earnings on Feb 18, 2025, during market hours.
Analysts project revenue of $173.23M, reflecting a 11.36% YoY growth and earnings per share of 0.03, making a 0.00% YoY.

Why Price Moved

1 day ago · Source New

-14.49%

NeoGenomics shares are trading lower after Benchma... Unlock content with Pro Subscription

4 days ago · Source

-20.63%

NeoGenomics shares are trading lower. The company announced its CEO will retire effective the first of April.

News

4 days ago · businesswire.com

NeoGenomics Announces Chief Executive Officer Succession

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' Chris Smith will retire as CEO and board member, effective April 1, 2025. Tony Zook will assume the role of CEO at that time.

1 week ago · businesswire.com

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

2 weeks ago · zacks.com

NeoGenomics (NEO) Upgraded to Buy: Here's Why

NeoGenomics (NEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · businesswire.com

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients.

1 month ago · businesswire.com

NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary CNS lymphoma at ASH.

1 month ago · businesswire.com

ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, ...

2 months ago · reuters.com

Airbus says A330NEO jet China certification progressing smoothly

The head of Airbus China said on Tuesday that the certification for its A330NEO plane in China was going smoothly and that the first delivery in the country could come in 2025.

2 months ago · businesswire.com

NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York City.

2 months ago · zacks.com

NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know

NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 months ago · seekingalpha.com

NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript

NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Execut...

2 months ago · zacks.com

NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics co...

2 months ago · zacks.com

Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade

The consensus price target hints at a 51.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...

3 months ago · businesswire.com

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024.